American Home withdraws new drug to ease pain, after death of 4 patients
Article Abstract:
The withdrawal of pain-reliever Duract by American Home Products Corp. follows the death of 4 patients and liver transplants in another 8 patients. Three other drugs, Redux, Pondimin and Verdia, had been previously recalled by American Home due to safety problems and FDA pressure. Roche Holding Ltd. also recently withdrew Posicor, a blood-pressure drug, and Warner-Lambert Co., owned by Glaxo Wellcome PLC, withdrew Rezulin, a diabetes drug, last year. Duract, which had been tested in about 2,500 patients and dispensed in 2.5 million prescriptions, has resulted in 12 serious liver cases. The drug recalls have caused some to question the FDA's streamlined drug-review process, but others claim that the recalls indicate a more effective FDA response.
Comment:
Pain reliever, Duract, recalled after 4 deaths and 8 liver transplants in patients
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Bristol-Myers announces major management shake-up; the race to succeed Heimbold in top spot is on among young hotshots
Article Abstract:
Major reorganization of top management at Bristol-Myers Squibb Co. begins with some taking new duties as of December 1, 1998, and preparing for possible advancement in the next one to three years. Chairman and CEO Charles A. Heimbold Jr. will retire in 2001 and executive vice president Kenneth E. Weg in 2000. Together they make up the "office of the chairman" which will groom others as they prepare for possibly taking over Weg's or Heimbold's positions.
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Strong Viagra sales propel Pfizer to 37% gain in quarterly profit
Article Abstract:
Pfizer Inc. posted an increase of 37% in its net income for the second-quarter of 1998. The improved net income resulted from the booming sales of the company's Viagra impotence drug and from major rises in other prescription drug sales. Pfizer's net income for the quarter was higher than what analysts expected. The company's net income is a harbinger for strong sales in other drug firms.
Comment:
Pfizer Inc. posts an increase of 37% in its net income for the second-quarter of 1998
Publication Name: The Wall Street Journal Western Edition
Subject: Business, general
ISSN: 0193-2241
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Pet project: Biotechs switch from drugs for man to drugs for man's best friends. FDA allows large-scale trial of AIDS vaccine
- Abstracts: Felton Bank seeks a new top executive. Agency lowers MBNA debt outlook. Finance mergers fought from a new angle
- Abstracts: Abbott clot-busting drug may extend window of time for treating patients. Oxford outlines plan to improve its performance
- Abstracts: American Air, British Air willing to delay alliance to win support. American Air raises leisure fares 4% except in hubs served by Northwest
- Abstracts: Home builders begin to see the advantages of consolidation. 'South Park' creators plan cartoon series for the Web